• Corsi e formazione continua
  • Istituto Oncologico della Svizzera Italiana
  • Ospedale Regionale di Bellinzona - San Giovanni
  • Parte 7 di 9

Conferenze Formative - Umberto Malapelle, IT

  • h. 12:00 - 13:00
  • Ospedale Regionale di Bellinzona, San Giovanni Disponibile online
Iscriviti al webinar
Conferenze Formative - Umberto Malapelle, IT

Gli eventi si terranno in modalità ibrida, sia online che in presenza presso l’Auditorium all’Ospedale Regionale di Bellinzona e Valli – Bellinzona

  • 24 gennaio
    Optimizing the designs of early clinical trials in oncology
    Christina Yap, UK,
    Professor of Clinical Trials Biostatistics, The Institute of Cancer Research, UK
  • 14 febbraio 
    Senolytic immune cells therapies for prostate cancer
    Andrea Alimonti, CH,
    Head of molecolar oncology at the Institute of Oncology Research (IOR-CH),
    Full Professor of Oncology USI, ETH, CH
    Full professor of Pharmacology UNiPD, IT
  • 27 marzo 
    The changing landscape of relapsed and refractory diffuse large B-cell lymphoma
    Andrew Davies, UK
    Professor of Haematological Oncology and Honorary Consultant, University of Southampton, UK
    Chair UK National Lymphoma Research Group
    Director Southampton Experimental Cancer Medicines Centre
  • 17 aprile 
    Advances in DDR targeting: what can we expect in the next years
    Timothy A Yap, USA
    Professor, Department of Investigational Cancer Therapeutics (Phase I Program)
    Vice President, Head of Clinical Development, Therapeutics Discovery Division
    Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
    The University of Texas MD Anderson Cancer Center
  • 15 maggio 
    Systematic reviews in a nutshell
    Giorgio Treglia, CH
    Medical education and Research Area and Imaging Institute of Southern Switzerland, EOC, Bellinzona
    Professor, Faculty of Biomedical sciences, USI, Lugano
    Faculty of Biology and Medicine, UNIL, Lausanne
  • 19 giugno 
    Management of antibody-drug conjugates toxicities
    Joseph Gligorov, FR
    Professor of Medical Oncology Sorbonne Université
    Medical Director of DMU ORPHé AP-HP Sorbonne Université
  • 18 settembre 
    ctDNA and MRD in solid tumors: current state and future directions
    Umberto Malapelle, IT
    Chair of Predictive Molecular Pathology Laboratory, Department of Public Health
    University Federico II of Naples, Italy
  • 23 ottobre 
    New KRAS inhibitors beyond G12C
    Fabrice Barlesi, FR
    General Director of Gustave Roussy
    Professor of Medicine at the Paris Saclay University, France
  • 20 novembre 
    Update on cellular therapies for solid tumours
    Andrew Furness, UK
    Consultant Medical Oncologist, Solid Tumour Cellular Therapy Lead, The Royal Marsden NHS Foundation Trust
    Team Leader and Clinical Lead, Centre for Translational Immunotherapy, The Institute of Cancer Research